(Sharecast News) - hVIVO announced on Thursday that it has signed a £6m clinical trial agreement with a clinical-stage biopharmaceutical company to conduct an influenza human challenge trial.
The AIM-traded clinical development company said the study would evaluate a monoclonal antibody for respiratory viral disease using its influenza human challenge study...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE